Volume 6, Issue 2 (12-2019)                   vacres 2019, 6(2): 1-8 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Abdel Aziz N, Tallima H, Abou El Dahab M, El Ridi R. Immunogenicity and Protective Capacity of Schistosoma haematobium Recombinant cathepsin L Against Infection of Hamsters with S. haematobium. vacres 2019; 6 (2) :1-8
URL: http://vacres.pasteur.ac.ir/article-1-164-en.html
Zoology Department, Faculty of Science, Cairo University
Abstract:   (1848 Views)
Introduction: Vaccination of hamsters with Schistosoma mansoni adjuvant-free recombinant cathepsin B1 (SmCB1) and L3 (SmCL3) have been shown to elicit highly significant (P < 0.005) protection against challenge Schistosoma haematobium that was not very superior to that achieved by the cysteine peptidase, papain.  Sterilizing immunity might, however, be induced if hamsters were vaccinated against S. haematobium infection with a homologous cysteine peptidase, i.e., S. haematobium cathepsin L (ShCL).   Methods: Standards methods, techniques, and primers based on the published nucleotide sequence of ShCL were used to clone, amplify and express DNAs encoding the target enzyme in a bacterial expression vector.  Repeat immunization trials were performed using recombinant ShCL alone or in combination with the vaccine candidate S. mansoni recombinant glyceraldehyde 3-phosphate dehydrogenase, in parallel with S. mansoni lecucine aminopeptidase.  Results: The results together indicated that our adjuvant-free, cysteine peptidase-based vaccine elicits highly significant (P < 0.0001) reduction in challenge worm burden and parasite egg viability.  Protection was associated with whole blood cultures release of type 1, type 2, and type 17 cytokines, and modest, yet significant (P < 0.05) humoral response to ShCL.  Conclusion: Sterilizing immunity was, however, not achieved in any trial, likely because of the preponderant role of cysteine peptidases-induced nonspecific factors in amplifying and antagonizing its protective potential.  Experiments are planned in an aim to identify these elusive factors and their exact role.
Full-Text [PDF 562 kb]   (481 Downloads)    
Type of Study: Original article | Subject: Vaccine development, efficacy and safety evaluation
Received: 2020/01/15

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2022 All Rights Reserved | Vaccine Research

Designed & Developed by : Yektaweb

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.